Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma: A prospective study

F. Crippa, M. Presti, A. Marini, B. D'Onofrio, G. Bolis, G. L. Buraggi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Twenty-five patients treated with debulking surgery and chemotherapy for ovarian cancer were prospectively studied to evaluate the efficacy of radioimmunoscintigraphy (RIS) in detecting residual tumor before second-look surgery. RIS was performed with the monoclonal antibody OC125 F (ab')2 labelled with I-131 without knowledge of clinical data and compared with subsequent surgical results. Second look showed tumor persistence in 12 patients, mostly characterized by small lesions. The overall diagnostic sensitivity of RIS was 50% and the specificity was 85%. In particular, RIS showed better sensitivity for pelvic tumor localizations than for abdominal sites (73% vs 33%); this was due to the inability of RIS to detect upper abdominal lesions. Therefore, our conclusion is that, at present, RIS cannot substitute surgical second-look in the management of ovarian cancer, however, considering that also ultrasonography, computer tomography and magnetic resonance are not always able to give definite diagnostic evidence in the follow-up of ovarian carcinoma, RIS could be added to these procedures to balance the limitations of each method. In this regard, the best application of RIS could be in the follow-up of patients with marker elevation without clinical evidence of disease, especially in the case of pelvic fibrosis or adhesions due to previous therapy, where the other non-invasive tools can give doubtful diagnostic results.

Original languageEnglish
Pages (from-to)103-108
Number of pages6
JournalInternational Journal of Biological Markers
Volume5
Issue number3
Publication statusPublished - 1990

Fingerprint

Radioimmunodetection
Tumors
Prospective Studies
Carcinoma
Surgery
Ultrasonography
Chemotherapy
Magnetic resonance
Tomography
Adhesion
Monoclonal Antibodies
Ovarian Neoplasms
Second-Look Surgery
Residual Neoplasm
Neoplasms
Fibrosis
Magnetic Resonance Spectroscopy
Drug Therapy

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma : A prospective study. / Crippa, F.; Presti, M.; Marini, A.; D'Onofrio, B.; Bolis, G.; Buraggi, G. L.

In: International Journal of Biological Markers, Vol. 5, No. 3, 1990, p. 103-108.

Research output: Contribution to journalArticle

Crippa, F, Presti, M, Marini, A, D'Onofrio, B, Bolis, G & Buraggi, GL 1990, 'Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma: A prospective study', International Journal of Biological Markers, vol. 5, no. 3, pp. 103-108.
Crippa, F. ; Presti, M. ; Marini, A. ; D'Onofrio, B. ; Bolis, G. ; Buraggi, G. L. / Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma : A prospective study. In: International Journal of Biological Markers. 1990 ; Vol. 5, No. 3. pp. 103-108.
@article{08b74ae610914e169c0603687fc4292e,
title = "Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma: A prospective study",
abstract = "Twenty-five patients treated with debulking surgery and chemotherapy for ovarian cancer were prospectively studied to evaluate the efficacy of radioimmunoscintigraphy (RIS) in detecting residual tumor before second-look surgery. RIS was performed with the monoclonal antibody OC125 F (ab')2 labelled with I-131 without knowledge of clinical data and compared with subsequent surgical results. Second look showed tumor persistence in 12 patients, mostly characterized by small lesions. The overall diagnostic sensitivity of RIS was 50{\%} and the specificity was 85{\%}. In particular, RIS showed better sensitivity for pelvic tumor localizations than for abdominal sites (73{\%} vs 33{\%}); this was due to the inability of RIS to detect upper abdominal lesions. Therefore, our conclusion is that, at present, RIS cannot substitute surgical second-look in the management of ovarian cancer, however, considering that also ultrasonography, computer tomography and magnetic resonance are not always able to give definite diagnostic evidence in the follow-up of ovarian carcinoma, RIS could be added to these procedures to balance the limitations of each method. In this regard, the best application of RIS could be in the follow-up of patients with marker elevation without clinical evidence of disease, especially in the case of pelvic fibrosis or adhesions due to previous therapy, where the other non-invasive tools can give doubtful diagnostic results.",
author = "F. Crippa and M. Presti and A. Marini and B. D'Onofrio and G. Bolis and Buraggi, {G. L.}",
year = "1990",
language = "English",
volume = "5",
pages = "103--108",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "3",

}

TY - JOUR

T1 - Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma

T2 - A prospective study

AU - Crippa, F.

AU - Presti, M.

AU - Marini, A.

AU - D'Onofrio, B.

AU - Bolis, G.

AU - Buraggi, G. L.

PY - 1990

Y1 - 1990

N2 - Twenty-five patients treated with debulking surgery and chemotherapy for ovarian cancer were prospectively studied to evaluate the efficacy of radioimmunoscintigraphy (RIS) in detecting residual tumor before second-look surgery. RIS was performed with the monoclonal antibody OC125 F (ab')2 labelled with I-131 without knowledge of clinical data and compared with subsequent surgical results. Second look showed tumor persistence in 12 patients, mostly characterized by small lesions. The overall diagnostic sensitivity of RIS was 50% and the specificity was 85%. In particular, RIS showed better sensitivity for pelvic tumor localizations than for abdominal sites (73% vs 33%); this was due to the inability of RIS to detect upper abdominal lesions. Therefore, our conclusion is that, at present, RIS cannot substitute surgical second-look in the management of ovarian cancer, however, considering that also ultrasonography, computer tomography and magnetic resonance are not always able to give definite diagnostic evidence in the follow-up of ovarian carcinoma, RIS could be added to these procedures to balance the limitations of each method. In this regard, the best application of RIS could be in the follow-up of patients with marker elevation without clinical evidence of disease, especially in the case of pelvic fibrosis or adhesions due to previous therapy, where the other non-invasive tools can give doubtful diagnostic results.

AB - Twenty-five patients treated with debulking surgery and chemotherapy for ovarian cancer were prospectively studied to evaluate the efficacy of radioimmunoscintigraphy (RIS) in detecting residual tumor before second-look surgery. RIS was performed with the monoclonal antibody OC125 F (ab')2 labelled with I-131 without knowledge of clinical data and compared with subsequent surgical results. Second look showed tumor persistence in 12 patients, mostly characterized by small lesions. The overall diagnostic sensitivity of RIS was 50% and the specificity was 85%. In particular, RIS showed better sensitivity for pelvic tumor localizations than for abdominal sites (73% vs 33%); this was due to the inability of RIS to detect upper abdominal lesions. Therefore, our conclusion is that, at present, RIS cannot substitute surgical second-look in the management of ovarian cancer, however, considering that also ultrasonography, computer tomography and magnetic resonance are not always able to give definite diagnostic evidence in the follow-up of ovarian carcinoma, RIS could be added to these procedures to balance the limitations of each method. In this regard, the best application of RIS could be in the follow-up of patients with marker elevation without clinical evidence of disease, especially in the case of pelvic fibrosis or adhesions due to previous therapy, where the other non-invasive tools can give doubtful diagnostic results.

UR - http://www.scopus.com/inward/record.url?scp=0025134584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025134584&partnerID=8YFLogxK

M3 - Article

C2 - 2286774

AN - SCOPUS:0025134584

VL - 5

SP - 103

EP - 108

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -